Results 201 to 210 of about 714,675 (285)

Activating the Osteoblastic USP26 Pathway Alleviates Multi‐Organ Fibrosis by Decreasing Insulin Resistance

open access: yesAdvanced Science, EarlyView.
The loss of Ubiquitin Specific Peptidase 26 (USP26) in osteoblasts results in decreased bone formation, as well as multi‐organ fibrosis associated with insulin resistance (IR). Mechanistically, the absence of USP26 reduces glycolysis and lactate accumulation, leading to decreased histone H3 lysine 18 lactylation (H3K18LA) in the promoter region of KH ...
Jiyuan Tang   +9 more
wiley   +1 more source

Remote Modulation of Single‐Atom Catalyst Boosts High‐Valent Cobalt–Oxo Species Generation for Water Purification and Detoxification

open access: yesAdvanced Science, EarlyView.
This study develops a phosphorus‐doped cobalt single‐atom catalyst that enhances high‐valent cobalt–oxo species generation for water purification. This atomic‐level tuning boosts the catalyst's activity by 3.5 times, enabling efficient pollutant degradation. A continuous‐flow reactor achieves high, long‐term removal efficiency, producing water with low
Wen‐Min Wang   +4 more
wiley   +1 more source

A Self‐Organized Liquid Reaction Container for Cellular Memory

open access: yesAdvanced Science, EarlyView.
How cells restore epigenetic information lost during replication is not known. This work proposes a mechanism based on the formation of biomolecular condensates. These condensates are induced by the chromosome itself and serve as reaction vessels for reconstructing missing epigenetic markers.
Sukanta Mukherjee   +4 more
wiley   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

open access: yesAdvanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy